• Lazard announced it will release its fourth quarter and full-year 2025 results on January 29, 2026, while separately confirming preliminary assets under management of about US$254.30 billion as of December 31, 2025, alongside modest net outflows.
• US authorities have charged a former Lazard junior banker with allegedly leaking confidential health-care deal information for insider trading, raising questions about internal controls just as the firm aims to grow its health-care advisory franchise.
• We’ll now assess how the insider trading charges against a former health-care banker could influence Lazard’s broader investment narrative and outlook.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Lazard Investment Narrative Recap

To own Lazard, you need to believe in its resilience as a global advisory and asset management firm, where fee-based client relationships and assets under management remain the key value drivers. The insider trading charges against a former junior banker appear reputational rather than financial for now, so the main short term focus still sits on near term deal activity and cost discipline, with the biggest risk being any hit to client trust in its healthcare franchise.

The upcoming January 29, 2026 release of fourth quarter and full year 2025 results looks especially relevant here, as it should give investors fresh detail on advisory revenue trends and any commentary on compliance and controls, right after Lazard reported about US$254.30 billion in assets under management with modest net outflows.

Yet behind the headlines, investors should be aware of how any erosion in client confidence around compliance could...

Lazard's narrative projects $4.2 billion revenue and $620.0 million earnings by 2028. This requires 11.3% yearly revenue growth and a $317.5 million earnings increase from $302.5 million today.

Uncover how Lazard's forecasts yield a $58.17 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently see Lazard’s fair value between US$47 and about US$77, reflecting a wide span of personal models. Set those views against the near term risk that compliance concerns in healthcare advisory could influence how comfortably Lazard converts its global mandate pipeline into sustained fee income.

Explore 4 other fair value estimates on Lazard - why the stock might be worth as much as 49% more than the current price!

Build Your Own Lazard Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Lazard research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Lazard research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lazard's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Find companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.